Many of these strategies have entered clinical development, and some have now advanced to phase III clinical trials. In the coming years, one or more of these new telomerase-targeting drugs may be expected to enter the pharmacopeia of standard care. Here, we briefly review the molecular functions of telomerase in cancer and provide an update about the preclinical and clinical development of telomerase targeting therapeutics.
Regulates telomere length and function. Required for the repression of telomere-adjacent gene expression and for normal meiosis or sporulation. It may be a negative regulator of the telomere-replicating enzyme, telomerase, or may protect against activation of telomerase-independent pathways of telomere elongation. It may be involved in the interactions between chromosomes and spindle proteins, disruption of these interactions would lead to defective meiosis.
Neurotoxicology. 2016 Jun 2. pii: S0161-813X(16)30100-0. doi: 10.1016/j.neuro.2016.05.022. [Epub ahead of print]
excerptTaken together, these data show that this optimized hTERT promoter-driving tyrosinase expression system might be a useful diagnostic tool for the detection of tumors using MR imaging.
oncogenotypes ina telomere length dependent manner google it
google it read conclusions
I believe it is 50% of whatever Asterias gets if they license a patent to someone other than that you are correct